New Inhaled Formulations for the Treatment of Asthma in Children and Adolescents

Kelly Jane Lunsford, PharmD

Disclosures

Pediatr Pharm. 2015;21(12) 

In This Article

Introduction

Asthma is the most common chronic condition affecting children in the United States. More than 10 million children under age 18 (14%) have been diagnosed with asthma and 6.8 million children (9%) remain with this condition.[1] Inhaled medications (e.g. inhaled corticosteroids and both short and long-acting beta2-agonists) are the mainstays of asthma treatment. Adherence to medication regimens involving the use of one or more inhaled formulations is often low, with some estimates suggesting that children generally take only 50–60% of prescribed doses.[2] Adherence is particularly problematic in the pediatric population owing to the coordination required to use some inhaled formations and dosing schedules requiring administration of these inhaled formulations two or three times a day. Additionally, many of these patients must rely on the assistance of caregivers for administration. Several new products have been developed which require less coordination between breath and dose actuation and less frequent dosing.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....